CSL is struggling to get the basics right. Although it takes time to turn around a sprawling business empire – as we’ll see at its results on Wednesday – it should be much easier to handle something ...

Skin disorders house Clinivel says a huge cash stockpile protects the company from "externalities" and enables its programs ...

Looking to make money fast? Here are some ways to make $100 or more in a single day to stack cash fast in your savings before ...

Mini-PCs sind kompakt, sparsam und leistungsstark – ideal für Office bis Gaming. Wir zeigen die besten Modelle aus über 80 Tests über alle Preisbereiche hinweg.

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL shares slumped, dragging down the market, after the healthcare giant mis-timed the announcement of its chief executive’s departure, leaving investors furious. At 4.05pm, just minutes before the ...

Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by Morningstar users in February 2026. Given February was earnings season, the trends ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...